Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
The END TB Strategy
Интеграция совместного оказания услуг в связи с ТБ и ВИЧ во всеобъемлющий пакет помощи для потребителей инъекционных наркотиков
International Journal of Infectious Diseases 32 (2015) 111–117
Данное руководство по применению групповой интерперсональной терапии (групповой ИПТ) в лечении депрессии дополняет собой mental health Gap Action Programme Intervention Guide (mhGAP-IG) («Рук...оводство mhGAP по принятию мер в отношении психических и неврологических расстройств») (WHO, 2016). Цель настоящего руководства заключается в предоставлении подробных инструкций по проведению групповой ИПТ, которая в соответствии с mhGAP является одним из первоочередных методов психологического лечения этого расстройства.
more
The WHO Mental Health Gap Action Programme (mhGAP) aims at scaling up mental health services in non-specialized health settings to achieve universal health coverage. The mhGAP operations manual is an integral component of the mhGAP package and supports district health managers and others responsible... for integrating mental and physical health services. The manual offers practical guidance and necessary tools for planning, preparing, implementing, monitoring and evaluating mhGAP
more
В последнее время вместо термина умственная отсталость все чаще используется понятие интеллектуальная недостаточность (ИН) (англ. – intellectual disability (ID)). Интеллектуал...ьная недостаточность или умственная отсталость – это состояние задержки или неполного развития психики, которое в первую очередь характеризуется нарушением способностей, возникающих в период созревания и обеспечивающих общий уровень интеллектуальности, то есть когнитивных, речевых, моторных и социальных способностей (World Health Organization, WHO, 1992).
more
This guide provides a practical overview of the process of developing a Theory of Change, focusing on using a stakeholder-driven, workshop approach to achieve this.
International Journal of Infectious Diseases 46 (2016) 56–60
International Journal of Infectious Diseases 32 (2015) 170–178
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ß 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:...//creativecommons.org/licenses/by-nc-nd/3.0/).
more
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
African Journal of Emergency Medicine
Volume 11, Issue 1, March 2021, Pages 132-139
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
interim guidance, 25 November 2024
An Illustrated Guide for Service Providers
This document is part of the process for improving the quality of care in family planning. Medical eligibility criteria for contraceptive use (MEC), the first edition of which was published in 1996, prsents current World Health Organization (WHO) guidance on the safety of various contraceptive e-
m...ethods for use in the context of specific health conditions and characteristics. This is the fifth edtion of the MEC –the latest in the series of periodic updates
more